Has Matthew Kaufman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,724 in general payments to Matthew Kaufman, MD across 79 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Kaufman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Kaufman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Kaufman, MD

Ophthalmology · Portland, ORNPI 1700014503

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (55.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Rxsight Inc accounts for 61.6% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $3,691, more than ten times the $168 reported in 2019. Among ophthalmology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,724in general payments, 2019–2025

Across 79 payments — averaging $97.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Rxsight Inc$5K
Alcon$2K
Johnson & Johnson Surgical Vision, Inc.$427
Glaukos Corporation$344
Mentor Worldwide LLC$133
Tearlab Corp$108
plus $71 from 1 others

What the payments were for

Consulting fees$3,37544%
Speaking & faculty fees$391%
Food & beverage$4,31056%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Rxsight Inc	24	$4,761
Alcon	33	$1,881
Johnson & Johnson Surgical Vision, Inc.	13	$427
Glaukos Corporation	4	$344
Mentor Worldwide LLC	1	$133
Tearlab Corp	1	$108
Tarsus Pharmaceuticals, Inc.	3	$71

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

RXSIGHT CONTACT LENS$4,359
RXSIGHT INJECTOR CARTRIDGE$4,359
RXSIGHT INJECTOR HANDPIECE$4,359
RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,359
LIGHT ADJUSTABLE LENS (LAL)$4,041
ARGOS$329
RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$318
Clareon$218
AcrySof IQ PanOptix$150
Hydrus Microstent$149
MENTOR MemoryGel Resterilizable Gel Sizer$133
TearLab Osmolarity System$108

How this compares

$7,724 in reported general payments places this provider in the 90th percentile of 248 ophthalmology providers in Oregon.

See all ophthalmology providers in Oregon →

Medicare billing

Part B allowed, 2024

$253,773

Medicare patients

734

Services billed

1,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LumiganBimatoprost	33	$18,300
RestasisCyclosporine	19	$16,694
Fluorometholone	181	$12,483
Latanoprost	529	$7,366
Travoprost	29	$5,537
Cyclosporine	12	$5,177
Brinzolamide	31	$4,660
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	187	$3,522
Brimonidine Tartrate	121	$3,173
Prednisolone Acetate	88	$3,105
Timolol Maleate	164	$2,349
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol	11	$1,286
Dorzolamide Hcl	63	$1,177
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	86	$1,077
Bimatoprost	11	$796

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Portland

Mark PennesiPortland$56K
Rene ChoiPortland$21K
Richard WeleberPortland$14K
Aazim SiddiquiPortland$13K
Richard StutzmanPortland$10K
Paul YangPortland$7K
Monia RedingPortland$5K
Richard DreyerPortland$5K
Andrea YongePortland$4K
Janani SingaraveluPortland$4K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →